Tamoxifen citrate loaded chitosan-gellan nanocapsules for breast cancer therapy: development, characterisation and in-vitro cell viability study

2018 ◽  
Vol 35 (3) ◽  
pp. 292-300 ◽  
Author(s):  
Pankaj Kumar Kathle ◽  
Nivedita Gautam ◽  
Karthikeyan Kesavan
Keyword(s):  
Breast Cancer ◽  
Cancer Therapy ◽  
Cell Viability ◽  
Breast Cancer Therapy ◽  
Tamoxifen Citrate ◽  
Viability Study ◽  
Therapy Development

scholarly journals Hydrogel-Mediated DOX⋅HCl/PTX Delivery System for Breast Cancer Therapy

2019 ◽  
Vol 20 (19) ◽  
pp. 4671
Author(s):  
Hoon Hyun ◽  
Young Yoo ◽  
So Kim ◽  
Hyun Ko ◽  
Heung Chun ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Therapy ◽  
Anticancer Effect ◽  
Breast Cancer Therapy ◽  
Glycol Chitosan ◽  
Burst Period ◽  
Delivery Approach ◽  
Dual Drug

We used a hydrogel-mediated dual drug delivery approach, based on an injectable glycol chitosan (GC) hydrogel, doxorubicin hydrochloride (DOX⋅HCl), and a complex of beta-cyclodextrin (β-CD) and paclitaxel (PTX) (GDCP) for breast cancer therapy in vitro and in vivo. The hydrogel was swollen over 3 days and remained so thereafter. After an initial burst period of 7 hours, the two drugs were released in a sustained manner for 7 days. The in vitro cell viability test showed that GDCP had a better anticancer effect than well plate and DOX⋅HCl/PTX (DP). In addition, the in vivo tests, which evaluated the anticancer effect, systemic toxicity, and histology, proved the feasibility of GDCP as a clinical therapy for breast cancer.

scholarly journals An analytical study of Trastuzumab-dendrimer-fluorine drug delivery system in breast cancer therapy in vitro

2021 ◽  
Vol 133 ◽  
pp. 111053
Author(s):  
Dorota Bartusik-Aebisher ◽  
Grzegorz Chrzanowski ◽  
Zuzanna Bober ◽  
David Aebisher
Keyword(s):  
Breast Cancer ◽  
Drug Delivery ◽  
Cancer Therapy ◽  
Drug Delivery System ◽  
Delivery System ◽  
Analytical Study ◽  
Breast Cancer Therapy

Novel folate-targeted docetaxel-loaded nanoparticles for tumour targeting: in vitro and in vivo evaluation

RSC Advances ◽  
2016 ◽  
Vol 6 (69) ◽  
pp. 64306-64314 ◽  
Author(s):  
M. H. Han ◽  
Z. T. Li ◽  
D. D. Bi ◽  
Y. F. Guo ◽  
H. X. Kuang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Folic Acid ◽  
Cancer Therapy ◽  
Targeted Delivery ◽  
Tumour Targeting ◽  
Breast Cancer Therapy ◽  
In Vivo Evaluation ◽  
Targeted Delivery System

Cholesterol-PEG1000-FA (folic acid) was synthesized as a stabilizer to encapsulate DTX, for the construction of a promising targeted delivery system for breast cancer therapy.

scholarly journals New Trends for Antimalarial Drugs: Synergism between Antineoplastics and Antimalarials on Breast Cancer Cells

Biomolecules ◽  
2020 ◽  
Vol 10 (12) ◽  
pp. 1623
Author(s):  
Diana Duarte ◽  
Nuno Vale
Keyword(s):  
Breast Cancer ◽  
Cancer Therapy ◽  
Cell Viability ◽  
Cultured Cells ◽  
Fixed Ratio ◽  
Tumor Cell Line ◽  
New Combination ◽  
Breast Cancer Therapy ◽  
Almost All ◽  
Mcf 7

Chemotherapy plays a key role in breast cancer therapy, but drug resistance and unwanted side effects make the treatment less effective. We propose a new combination model that combines antineoplastic drugs and antimalarials for breast cancer therapy. Cytotoxic effects of two antineoplastic agents alone and in combination with several antimalarials on MCF-7 tumor cell line was evaluated. Different concentrations in a fixed ratio were added to the cultured cells and incubated for 48 h. Cell viability was evaluated using MTT and SRB assays. Synergism was evaluated using the Chou-Talalay method. The results indicate doxorubicin (DOX) and paclitaxel (PTX) alone at concentrations of their IC50 and higher are cell growth inhibitors. Mefloquine, artesunate, and chloroquine at concentrations of their IC50 demonstrate anti-cancer activity. In combination, almost all antimalarials demonstrate higher ability than DOX and PTX alone to decrease cell viability at concentrations of IC50 and lower than their IC50. The combination of chloroquine, artesunate and mefloquine with DOX and PTX was synergic (CI < 1). The combination of DOX and mefloquine after 48 h incubation demonstrated the highest cytotoxicity against MCF-7 cells, and the combination of DOX and artesunate was the most synergic. These results suggest antimalarials could act synergistically with DOX/PTX for breast cancer therapy.

Sign in / Sign up

Export Citation Format

Share Document